NCT00455403View on ClinicalTrials.gov

Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)

NACompletedINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Metabolic Syndrome XOverweightHypertensionDyslipidemiasPrediabetic State
Interventions
DRUG

Chloroquine

One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24

DRUG

Placebo Comparator

Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Singulex
All Listed Sponsors
lead

Washington University School of Medicine

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Singulex

INDUSTRY